The PALB2 (Partner and Localizer of BRCA2) antibody is a crucial tool in studying the molecular role of the PALB2 protein, a tumor suppressor integral to DNA repair and genome stability. PALB2 interacts with BRCA1 and BRCA2. forming the BRCA-PALB2-BRCA2 axis essential for homologous recombination repair (HRR) of double-strand breaks. Mutations in PALB2 are linked to hereditary cancers, particularly breast, pancreatic, and ovarian cancers, with pathogenic variants significantly elevating cancer risk. Researchers use PALB2 antibodies to detect and quantify PALB2 protein expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). These antibodies help assess PALB2’s functional status, subcellular localization, and interactions with binding partners, aiding in understanding its role in HRR and cancer pathogenesis. Clinically, PALB2 antibody-based assays may complement genetic testing to evaluate cancer risk or therapy response, as PALB2-deficient tumors often exhibit sensitivity to PARP inhibitors or platinum-based chemotherapy. However, antibody specificity and validation remain critical, as cross-reactivity or batch variability can affect data reliability. Ongoing research focuses on optimizing PALB2 antibodies for diagnostic and prognostic applications, potentially improving personalized cancer management strategies.